• If you are wondering whether STERIS at around US$212 a share offers good value or if you are better off waiting on the sidelines, this article walks through what the current price might be implying.
• The stock has been weak recently, with the share price down about 1.8% over the last week, 0.8% over the last month, 14.9% year to date and 12.4% over the past year. These moves may change how you view its risk and reward trade off.
• Recent coverage around STERIS has focused on its role within healthcare equipment and services and how that positioning fits into broader sector trends. This context helps frame whether the recent share price moves reflect sentiment shifts or longer term questions about what investors are willing to pay for the stock.
• Right now, STERIS has a valuation score of 2 out of 6. The sections that follow will compare different valuation approaches and also point to a more complete way to think about value toward the end of this article.

STERIS scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: STERIS Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts those projected amounts back to today’s dollars to estimate what the business might be worth right now.

For STERIS, the latest twelve month Free Cash Flow is about $946.7 million. Analysts and model estimates point to Free Cash Flow of $977.9 million in the year to March 2028, with further projections out to 2035 based on Simply Wall St extrapolations. Over the next 10 years, those projected cash flows are discounted back to today using a 2 Stage Free Cash Flow to Equity approach. These values are then combined to arrive at an intrinsic value estimate.

On this basis, the DCF model suggests a fair value of about $225.85 per share, compared with a current share price around $212. That implies the stock is trading at roughly a 5.8% discount to this intrinsic value estimate, which sits in a range that can be considered broadly in line with fair value.

Result: ABOUT RIGHT

STERIS is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: STERIS Price vs Earnings

For a profitable company, the P/E ratio is a useful shorthand because it links what you pay for the stock to the earnings it is currently generating. The higher the expected earnings growth and the lower the perceived risk, the higher the P/E ratio investors are usually willing to accept as “normal” for that stock.

STERIS currently trades on a P/E of about 26.7x. That sits above the Medical Equipment industry average of around 24.2x and the peer group average of about 21.1x, suggesting the stock is priced at a higher earnings multiple than many of its sector peers.

Simply Wall St’s Fair Ratio framework estimates that, given factors such as STERIS’ earnings profile, profit margins, industry, market cap and risk characteristics, a P/E of about 23.6x would be more in line with those fundamentals. This Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for company specific drivers rather than treating all stocks in the group as identical. Comparing the Fair Ratio of 23.6x with the current P/E of 26.7x points to STERIS trading somewhat above this model based reference level.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your STERIS Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you attach a clear story to your STERIS numbers by linking your view of its future revenue, earnings and margins to a forecast and then to a fair value. This updates automatically when new news or earnings arrive, so you can compare that fair value with the current price and decide whether the stock fits your plan, whether you lean closer to a higher fair value view around US$300 that assumes stronger growth and higher future P/E, or a more cautious stance nearer US$231 that includes more risks around tariffs, healthcare payments, M&A execution, bioprocessing demand and regulatory costs.

Do you think there's more to the story for STERIS? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.